Research

At Pharvis, we strive for a healthier and happier life for every family.

R&D pipeline
Project code PA501
Mode of action
  • Leukotrien B4 receptor 2 inhibitor (BLT2 inhibitor)
Indication
  • Severe asthma
Development stage
Discovery Preclinical Phase1 Phase2 Phase3 Approval
Patent 1
Patent No.  :  10 - 1796391
Date of Patent : Nov. 3, 2017
Novel compound having  BLT inhibitory activity and composition for preventing or treating inflammatory
diseases, comprising same as active ingredient
(Group 1,  ethynyl)  
Patent 2
Patenr No. : US 10,179,764 B2
Date of Patent : Jan. 15, 2019
Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient
Patent 3
Patent No.  :  10 - 1796390
Date of Patent : Nov. 3, 2017
[Novel compound having  BLT inhibitory activity and composition for preventing or treating inflammatory
diseases, comprising same as active ingredient (Group 4,  biphenyl)  
Project code
  • PA501
Mode of action
  • GPR119 agonist
Indication
  • NASH
Development stage
Discovery Preclinical Phase1 Phase2 Phase3 Approval
Patent 1
Patent No.  :  10 – 1665846
Date of Patent : Sep. 6, 2016
Pharmaceutical composition for preventing or treating Of nonalcoholic fatty liver disease comprising G protein coupled receptor 119 ligand as an active ingredient
Patent 2
Patenr No. : US 9,895,370 B2
Date of Patent : Feb. 20, 2018
Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising gprotein coupled receptor 119 LIGAND as an active ingredient
Patent 3
Patent No.  :  10 - 1946516
Date of Patent : Jan. 31, 2019
Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient